Track subtle changes Appetite reduction is often gradual, not dramatic
Individual outcomes tend to vary depending on various factors including adherence, starting weight, and levels of physical activity
Across the trial outcome in human beings who do not suffer from type 2 diabetes, a median weight loss of 17 % - 18 % assisted for 68 weeks was disclosed for people with obesity medicated with Semaglutide
however, conclusive clinical efficacy data (on how the drug controls glucose metabolism) are currently still lacking. Looking ahead, the company that developed the drug, Atrogi AB, plans to conduct a larger phase 2 clinical trial with a larger, more diverse population, including people with obesity
Follow-up of a healthy lifestyle education program (the edal study): Four years after cessation of randomized controlled trial intervention